The mission of DTC/DTS focuses on developing novel diagnostics and therapies for cancer. These groups are working together to generate biomarkers and therapeutics that span initial research efforts through late-phase clinical trials. Clinicians, research nurses, and support staff from both groups have extensive experience with early-phase combination and single-agent studies and provide outstanding clinical care for patients with advanced malignancies. Over the past four years, DTC/DTS has continued to conduct early-phase clinical trials which have resulted in a number of publications and is coordinating several multicenter trials to open at leading drug development centers across the US.
|Kelly, Ronan J; Rajan, Arun; Force, Jeremy et al. (2011) Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 17:1190-9|
|Jain, Lokesh; Woo, Sukyung; Gardner, Erin R et al. (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294-305|
|Kummar, Shivaani; Gutierrez, Martin E; Gardner, Erin R et al. (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46:340-7|
|Jain, Lokesh; Sissung, Tristan M; Danesi, Romano et al. (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95|